Chapter 3 Cerebrovascular and Cardiovascular Pathology in Alzheimer's Disease

International Review of Neurobiology

Volumn 84, Issue , 2009, Pages 35-48

  de la Torre, Jack C ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; MEMANTINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DIZZINESS; DOPPLER ECHOGRAPHY; DRUG INDUCED HEADACHE; DRUG MECHANISM; ECHOCARDIOGRAPHY; EXERCISE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; NAUSEA; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOMITING; BRAIN; BRAIN CIRCULATION; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; BRAIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; HUMANS; NEURONS; RISK FACTORS;

EID: 66249115618     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)00403-6     Document Type: Review

References (32)

1. Aguero-Torres H., Kivipelto M., and von Strauss E. Rethinking the dementia diagnoses in a population-based study: What is Alzheimer's disease and what is vascular dementia? A study from the Kungsholmen project. Dement. Geriatr. Cogn. Disord. 22 3 (2006) 244-249
2. Ahmed S.N., Syed F.M., and Porembka D.T. Echocardiographic evaluation of hemodynamic parameters. Crit. Care Med. 35 8 Suppl. (2007) S323-S329
3. Alves T.C., and Busatto G.F. Regional cerebral blood flow reductions, heart failure and Alzheimer's disease. Neurol. Res. 28 (2006) 579-587
4. Alves T.C., and Busatto G.F. Regional cerebral blood flow reductions, heart failure and Alzheimer's disease. Neurol. Res. 28 6 (2006) 579-587
5. Breteler M.M. Vascular risk factors for Alzheimer's disease: An epidemiologic perspective. Neurobiol. Aging 21 2 (2000) 153-160
6. de la Torre J.C., and Mussivand T.C. Can disturbed brain microcirculation cause Alzheimer's disease?. Neurol. Res. 15 (1993) 146-153
7. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging 903 (2000) 424-436
8. de la Torre J.C. Alzheimer's disease is a vasocognopathy: A new term to describe its nature. Neurological. Res. 26 5 (2004) 517-524
9. de la Torre J.C. Is Alzheimer's a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol. 3 (2004) 184-190
10. de la Torre J.C. How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurol. Res. 28 (2006) 637-644
11. de Leeuw F.E., Barkhof F., and Scheltens P. White matter lesions and hippocampal atrophy in Alzheimer's disease. Neurology 62 (2004) 310-312
12. de la Torre J.C. Alzheimer disease prevalence be lowered with non-invasive testing. J. Alzheimer Dis. 14 3 (2008) 353-359
13. de la Torre J.C. Carotid artery ultrasound and echocardiography (CAUSE) testing to lower the prevalence of Alzheimer's disease. J. Stroke Cerebrovasc. Dis. (2009) in press
14. de Leon M.J., Convit A., and Wolf O.T. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98 (2001) 10966-10971
15. Elias M.F., Wolf P.A., D'Agostino R.B., Cobb J., and White L.R. Blood pressure level is inversely related to cognitive functioning: The Framingham Study. Am. J. Epidemiol. 138 6 (1993) 353-364
16. Endres M., Laufs U., and Huang Z. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. PNAS 95 (1998) 8880-8885
17. Grundy S.M., Cleeman J.I., Daniels S.R., and Donato K.A. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
18. Ivan C.S., Seshadri S., and Beiser A. Dementia after stroke: The Framingham Study. Stroke 35 (2004) 1264-1268
19. Johnson K.A., Jones K., Holman B.L., Becker J., Spiers P.A., Satlin A., and Albert M.S. Prediction of Alzheimer's disease using SPECT. Neurology 50 (1998) 1563-1571
20. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 12 (1998) 1129-1135
21. Leenders K.L., Perani D., Lammertsma A.A., Heather J.D., Buckingham P., Healy M.J., Gibbs J.M., Wise R.J., Hatazawa J., and Herold S. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 113 (1990) 27-47
22. Loveman E., Green C., Kirby J., Takeda A., Picot J., Payne E., and Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol. Assess 10 1 (2006) 1-160 iii-iv, ix-xi
23. Martins I.J., Hone E., Foster J.K., Sunram-Lea S.I., Gnjec A., Fuller S.J., Nolan D., Gandy S.E., and Martins R.N. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol. Psychiatry 11 8 (2006) 721-736
24. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol. Res. 25 6 (2003) 605-610
25. Ruitenberg A., den Heiker T., and Bakker S.L. Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study. Ann. Neurol. 57 (2005) 789-794
26. Sjogren M., Mielke M., Gustafson D., Zandi P., and Skoog I. Cholesterol and Alzheimer's disease-is there a relation?. Mech. Ageing Dev. 127 2 (2006) 138-147
27. Silverman D.H., and Phelps M.E. Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: Normal development, aging, dementia, and stroke. Mol. Genet. Metab. 74 1-2 (2001) 128-138
28. Sismondo S. How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Soc. Sci. Med. 66 9 (2008) 1909-1914
29. Sparks D.L., Sabbagh M.N., and Connor D.J. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch. Neurol. 62 (2005) 753-757
30. Vanhanen M., Koivisto K., Moilanen L., Helkala E.L., Hanninen T., Soininen H., Kervinen K., Kesaniemi Y.A., Laakso M., and Kuusisto J. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 67 5 (2006) 843-847
31. Velliquette R.A., O'Connor T., and Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25 (2005) 10874-10883
32. Wolozin B., Kellman W., Ruosseau P., Celesia G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443